Legend Biotech Corporation (LEGN) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-03, Legend Biotech Corporation (NASDAQ: LEGN) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $21.10 (-2.45% 1D, market cap $4.21B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, LEGN ranks #162 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LEGN carries a Roarable C- (60/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, EWTX (Edgewise Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -31.9%, cap $4.22B) and INDV (Indivior Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E 19.8x, ROIC 62.2%, cap $4.17B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).
For Legend Biotech Corporation (LEGN), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs and sector rank #162 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
SEC Form 4 / 13F Thermometer: 60% Net Buy • Cannibal Buyback (-1.24% YoY Shares)
Macro rate sensitivity & RSI-14 (59.2) create a -10 pt regime headwind
Even with a 60/100 (C-) score, LEGN faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($19.60) or 200D SMA ($22.13) invalidates the momentum regime and cuts Target Base ($21.29) toward Bear Floor ($16.61).
Legend Biotech Corporation (LEGN) dropped -2.45% to $21.10, trading at 23% of its 52-week range ($16.24 – $37.5). Solid steady margins (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
Yahoo Finance report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.
Key TakeawaysA $2 billion fund’s latest 13F shows its three biggest adds in the quarter ended June 30 were Viridian Therapeutics, Travere Therapeutics, and Legend Biotech. Analysts’ average price targets sit 47% to 111%
Legend Biotech has seen its stock swing sharply in recent years, while fresh progress on its CAR T pipeline has kept it on investors' radar. With the share price around US$21.56 after those moves, the live question is wh
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +9.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on LEGN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for LEGN. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Legend Biotech Corporation (LEGN) ranks #162 by composite RQD confidence (60/100, grade C-) and #174 by equity capitalization ($4.21B). Within this direct 5-issuer industry benchmark cohort, INDV leads on earnings valuation at 19.8x trailing P/E, while INDV leads on capital efficiency and profitability with 62.2% ROIC and 80.2% gross margin. LEGN currently leads its immediate peer cohort in composite quantitative strength at 60/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LEGN
ACTIVE
Legend Biotech Corporation | C- | 60/100 | 32.8x | — | 9.9% | -2.45% | $4.21B | Benchmark Subject |
| EWTX Edgewise Therapeutics Inc. | D- | 41/100 | — | — | -31.9% | -2.03% | $4.22B | /ewtx-vs-legn → |
| INDV Indivior Pharmaceuticals Inc. | D | 51/100 | 19.8x | 80.2% | 62.2% | +0.34% | $4.17B | /indv-vs-legn → |
| LQDA Liquidia Corporation | D- | 36/100 | — | — | -12.6% | -7.12% | $4.03B | /lqda-vs-legn → |
| ARQT Arcutis Biotherapeutics Inc. | D+ | 54/100 | — | 90.2% | -3.0% | -2.53% | $4.03B | /arqt-vs-legn → |
Legend Biotech Corporation (LEGN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $4.21B, trailing P/E of 32.8x, forward P/E of 30.5x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.
As of 2026-11-03, Legend Biotech Corporation (NASDAQ: LEGN) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $21.10 (-2.45% 1D, market cap $4.21B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, LEGN ranks #162 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LEGN carries a Roarable C- (60/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, EWTX (Edgewise Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -31.9%, cap $4.22B) and INDV (Indivior Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E 19.8x, ROIC 62.2%, cap $4.17B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).
For Legend Biotech Corporation (LEGN), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs and sector rank #162 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
LEGN last traded at $21.10 (-2.45% on volume of 1,133,847 shares), positioning the stock +7.65% above its 50-day simple moving average ($19.60) and -4.65% below its 200-day simple moving average ($22.13). Across its 52-week range of $16.24 to $37.50, LEGN sits at the 22.9% percentile with a 14-day RSI of 59.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.0% ($18.78 to $23.42).
Legend Biotech Corporation (LEGN) earns a live Roarable RQD composite score of 60/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $21.10 (-2.45% 1D, market capitalization $4.21B).
Legend Biotech Corporation is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It carries a market capitalization of $4.3B.
No upstream or downstream links, sector correlations, or 2nd-order bottlenecks are recorded. — for supplier, partner, or customer dependencies.
Real-time company headlines, analyst actions, and sector developments for Legend Biotech Corporation (LEGN) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Legend Biotech Corporation (LEGN) market action, institutional positioning, and fundamental catalysts.
Don't sleep on LEGN's setup in Health Care. Balance-sheet strength (Altman Z 3.74, Piotroski F 8/9, Debt/Equity 0.39) scores highest among the RQD pillars.. Beta of 1.04 means it moves fast when momentum turns, and the 5-pillar RQD gauge (60/100) backs up the fundamental quality.
@ShortSeller_Dan Fair point on 32.8x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
Fading this rally in LEGN at $21.63. Valuation is demanding at 32.8 TTM P/E with a thin 2.21% FCF yield and modest 9.9% ROIC.. With a beta of 1.04 and the stock sitting at $21.63 (52-wk range $16.24–$37.50), the easy multiple expansion is already priced in.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).